Literature DB >> 21082928

Minimal residual disease in acute myeloid leukemia: already predicting a safe haven?

Gerrit Jan Schuurhuis, Gert Ossenkoppele.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21082928     DOI： 10.1586/ehm.09.69

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN： 1747-4094            Impact factor:   2.929


× No keyword cloud information.
  4 in total

1.  Time-Delayed Integration-Spectral Flow Cytometer (TDI-SFC) for Low-Abundance-Cell Immunophenotyping.

Authors:  Wenting Hu; Steven A Soper; J Matt Jackson
Journal:  Anal Chem       Date:  2019-03-13       Impact factor: 6.986

2.  Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.

Authors:  W Zeijlemaker; A Kelder; Y J M Oussoren-Brockhoff; W J Scholten; A N Snel; D Veldhuizen; J Cloos; G J Ossenkoppele; G J Schuurhuis
Journal:  Leukemia       Date:  2015-09-16       Impact factor: 11.528

3.  Microfluidics for the detection of minimal residual disease in acute myeloid leukemia patients using circulating leukemic cells selected from blood.

Authors:  Joshua M Jackson; James B Taylor; Małgorzata A Witek; Sally A Hunsucker; Jennifer P Waugh; Yuri Fedoriw; Thomas C Shea; Steven A Soper; Paul M Armistead
Journal:  Analyst       Date:  2016-01-21       Impact factor: 4.616

4.  PLCB4 upregulation is associated with unfavorable prognosis in pediatric acute myeloid leukemia.

Authors:  Shiwen Wu; Wei Zhang; Dongqin Shen; Jianle Lu; Li Zhao
Journal:  Oncol Lett       Date:  2019-09-25       Impact factor: 2.967
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.